Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 496

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 1B
Chunk 496
---
 was estimated using the Black-Scholes option valuation model using the following assumptions:

			Year Ended September 30, 2024

			Risk free interest rate

			4.92
			%

			Expected life (years)

			5

			Expected share price volatility

			97.26
			%

			Expected dividend yield

			0.00
			%

As of September 30, 2025, the Company had approximately $0.01 million of unrecognized share-based compensation expense, which is expected to be recognized over a period of 12 months.

Restricted share units

The Company's 2019 Plan allows restricted share units (“RSUs”) to be granted to directors, officers, employees and certain external consultants and advisers. Under the 2019 Plan, the RSU term is not to exceed 10 years. The fair value of RSUs is determined based on the market price of the Company’s common shares on the grant date.

The following is a summary of changes in the status of RSUs from October 1, 2024 through September 30, 2025: 

			Number of RSU

			Weighted Average Grant Date Fair Value

			Balance - September 30, 2023

			33,045

			$
			5.60

			Granted

			30,159

			4.56

			Balance - September 30, 2024

			63,204

			$
			5.10

			Granted

			1,227,807

			$
			2.01

			Exercised

			(31,591
			)
			 
			$
			2.27

			Forfeited

			(7,230
			)
			 
			$
			1.99

			Cancelled

			(8,537
			)
			 
			$
			1.99

			Balance - September 30, 2025

			1,243,653

			$
			2.16

The following table summarizes information about the RSUs under the 2019 Plan outstanding and exercisable at September 30, 2025:

			Number of RSU

			Exercisable at
			September 30, 2025 (#) 

			Expiry